Allogene Therapeutics Inc (ALLO)
2.97
+0.05
(+1.71%)
USD |
NASDAQ |
May 02, 16:00
2.96
-0.01
(-0.34%)
After-Hours: 20:00
Allogene Therapeutics Enterprise Value: 53.51M for May 2, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 02, 2024 | 53.51M |
| May 01, 2024 | 45.05M |
| April 30, 2024 | 18.00M |
| April 29, 2024 | 31.52M |
| April 26, 2024 | 39.98M |
| April 25, 2024 | 34.06M |
| April 24, 2024 | 65.34M |
| April 23, 2024 | 121.14M |
| April 22, 2024 | 126.22M |
| April 19, 2024 | 138.05M |
| April 18, 2024 | 136.36M |
| April 17, 2024 | 144.82M |
| April 16, 2024 | 143.12M |
| April 15, 2024 | 151.58M |
| April 12, 2024 | 193.85M |
| April 11, 2024 | 225.98M |
| April 10, 2024 | 239.51M |
| April 09, 2024 | 246.27M |
| April 08, 2024 | 224.29M |
| April 05, 2024 | 220.91M |
| April 04, 2024 | 236.13M |
| April 03, 2024 | 242.89M |
| April 02, 2024 | 239.51M |
| April 01, 2024 | 291.93M |
| March 28, 2024 | 307.14M |
| Date | Value |
|---|---|
| March 27, 2024 | 305.45M |
| March 26, 2024 | 263.18M |
| March 25, 2024 | 276.71M |
| March 22, 2024 | 271.63M |
| March 21, 2024 | 291.93M |
| March 20, 2024 | 300.38M |
| March 19, 2024 | 293.62M |
| March 18, 2024 | 260.64M |
| March 15, 2024 | 339.27M |
| March 14, 2024 | 311.37M |
| March 13, 2024 | 376.47M |
| March 12, 2024 | 379.85M |
| March 11, 2024 | 408.01M |
| March 08, 2024 | 438.36M |
| March 07, 2024 | 490.64M |
| March 06, 2024 | 500.76M |
| March 05, 2024 | 461.97M |
| March 04, 2024 | 472.09M |
| March 01, 2024 | 384.40M |
| February 29, 2024 | 379.34M |
| February 28, 2024 | 414.75M |
| February 27, 2024 | 418.12M |
| February 26, 2024 | 332.12M |
| February 23, 2024 | 316.94M |
| February 22, 2024 | 286.58M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-81.83M
Minimum
Nov 29 2023
6.280B
Maximum
May 22 2020
1.996B
Average
1.984B
Median
Enterprise Value Benchmarks
| Agenus Inc | 211.42M |
| ANI Pharmaceuticals Inc | 1.502B |
| Vaxart Inc | 90.51M |
| aTyr Pharma Inc | 10.05M |
| PAVmed Inc | 77.91M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -89.26M |
| Revenue (Quarterly) | -0.044M |
| Total Expenses (Quarterly) | 71.88M |
| EPS Diluted (Quarterly) | -0.54 |
| Earnings Yield | -71.38% |
| Normalized Earnings Yield | -71.38 |